scholarly article | Q13442814 |
P50 | author | Michael W Parker | Q41147578 |
Angel F. Lopez | Q42799423 | ||
David Ross | Q42884508 | ||
Jeffrey J Babon | Q56882450 | ||
Timothy R Hercus | Q62554539 | ||
Nicholas P D Liau | Q86251815 | ||
Denis Tvorogov | Q89983184 | ||
Daniel Thomas | Q93379945 | ||
P2093 | author name string | Ravindra Majeti | |
Vinay Tergaonkar | |||
Timothy P Hughes | |||
Winnie L Kan | |||
Emma F Barry | |||
Mara Dottore | |||
Frank Stomski | |||
Maya Lathi | |||
P2860 | cites work | Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization | Q24311715 |
Identification of a hierarchy of multipotent hematopoietic progenitors in human cord blood | Q24656265 | ||
Janus kinase deregulation in leukemia and lymphoma | Q26991810 | ||
Modulation of Activation-Loop Phosphorylation by JAK Inhibitors Is Binding Mode Dependent | Q27681086 | ||
Jak2 is essential for signaling through a variety of cytokine receptors | Q28270987 | ||
Establishment and characterization of a new human megakaryoblastic cell line (SET-2) that spontaneously matures to megakaryocytes and produces platelet-like particles | Q33331222 | ||
Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis | Q33397838 | ||
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis | Q33399980 | ||
Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation | Q33416494 | ||
Leukemic diffuse large B-cell lymphoma in a patient with myeloproliferative disorder. | Q33420865 | ||
Mechanism of activation of protein kinase JAK2 by the growth hormone receptor | Q34420222 | ||
CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms. | Q34485103 | ||
A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses. | Q36565214 | ||
Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors. | Q37708936 | ||
The JAK-STAT pathway at twenty | Q38004201 | ||
Calreticulin mutants in mice induce an MPL-dependent thrombocytosis with frequent progression to myelofibrosis | Q38816577 | ||
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy | Q38824881 | ||
Dimerization by a cytokine receptor is necessary for constitutive activation of JAK2V617F. | Q40031223 | ||
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders | Q40330808 | ||
JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response. | Q40960930 | ||
Thrombopoietin receptor is required for the oncogenic function of CALR mutants. | Q42365043 | ||
Ruxolitinib withdrawal syndrome leading to tumor lysis | Q44277096 | ||
A life-threatening ruxolitinib discontinuation syndrome | Q47906964 | ||
Recurrent hypoxemic respiratory failure. Beyond the usual suspects. | Q51696636 | ||
Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin. | Q53204648 | ||
Simultaneous antagonism of interleukin-5, granulocyte-macrophage colony-stimulating factor, and interleukin-3 stimulation of human eosinophils by targetting the common cytokine binding site of their receptors | Q78225288 | ||
P433 | issue | 11 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | myelofibrosis | Q1752571 |
phosphorylation | Q242736 | ||
P304 | page(s) | eaat3834 | |
P577 | publication date | 2018-11-01 | |
P1433 | published in | Science Advances | Q19881044 |
P1476 | title | Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis | |
P478 | volume | 4 |
Q92354392 | Characterization of JAK1 Pseudokinase Domain in Cytokine Signaling |
Q92340076 | Constitutive STAT5 phosphorylation in CD34+ cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity |
Q89682918 | Inhibition of USP9X Downregulates JAK2-V617F and Induces Apoptosis Synergistically with BH3 Mimetics Preferentially in Ruxolitinib-Persistent JAK2-V617F-Positive Leukemic Cells |
Q91198796 | Ruxolitinib binding to human serum albumin: bioinformatics, biochemical and functional characterization in JAK2V617F+ cell models |
Search more.